Quick Answer
Inhibrx Biosciences, Inc. reported Earnings Per Share Diluted of $9.04 (loss) per share for the year ending 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -108.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $4.31 (loss) per share | Q3 2023: $4.39 (loss) per share | Q1 2024: $5.77 (loss) per share | Q2 2024: $125.48 per share | Q3 2024: $2.84 (loss) per share | Q1 2025: $2.80 (loss) per share | Q2 2025: $1.85 (loss) per share | Q3 2025: $2.28 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Earnings Per Share Diluted has grown by 55.9%.
- Historical annual values: Fiscal year 2025: $9.04 (loss) per share | Fiscal year 2024: $112.62 per share | Fiscal year 2023: $20.48 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: